M&A
Lundbeck reportedly seeks to acquire US pharma company Xeris Biopharma
September 30, 2026
Biotech
M&A
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
Lundbeck, Xeris Biopharma, Bloomberg
Date
September 30, 2026
Danish pharmaceutical company Lundbeck is reportedly working with advisers to explore a takeover of Chicago-based Xeris Biopharma, per Bloomberg News. The report cites unnamed sources and follows a 1.6% stock rise for Xeris on Tuesday, adding to an 8.0% gain on Monday.
Xeris has three marketed products: Recorlev for Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis. The company reported Q2 revenue of $92m, with Recorlev growing 80% year-over-year to just under $57m.
Lundbeck, a Danish public company with a market cap of $6.6bn, is the acquirer. Xeris Biopharma, a US public company with a $1.8bn market cap, is the target. A Xeris spokesperson told Bloomberg the company 'is not for sale,' while Lundbeck has not responded to inquiries.
Customers and partners in Xeris's therapeutic areas—endocrinology, neurology, and rare diseases—could see changes in product strategy, supply chain, or commercial focus if the deal proceeds.
The reported acquisition would expand Lundbeck's portfolio into new therapeutic areas and leverage Xeris's ready-to-use injection formulation technology. For the market, this signals continued consolidation in biotech, with larger pharma companies acquiring smaller players with marketed products and growth assets.
Watch for official statements from either company, as well as any regulatory filings or due diligence leaks. The 'not for sale' stance from Xeris could be a negotiation tactic or a genuine rejection, which may affect deal timing and terms.
Also monitor Lundbeck's financing strategy and whether other bidders emerge. For sales reps, this is the moment to identify integration, regulatory, and post-merger service needs at both companies—before the deal is finalized or falls through.
Source:
medwatch.comGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
